Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded nasal spray containing capsaicin, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
In FDA-approved products, capsaicin appears only as a component of kits.
This dose form is water-containing (aqueous). Under USP <795>, aqueous preparations carry shorter default beyond-use dates than nonaqueous ones, and a preservative in the base allows a longer date than no preservative. The date printed on the label is the one to follow.
Capsaicin is the chili pepper compound used as a topical pain reliever; compounding pharmacies prepare it in creams, gels and ointments by prescription.
Capsaicin is the molecule that makes chili peppers hot. It binds TRPV1, a receptor on pain-sensing nerve endings in the skin. At first it fires those nerves, which is why it burns; with repeated or high exposure the nerve endings pull back and stop signaling, and pain in that area quiets until the fibers regrow. Over-the-counter capsaicin creams, gels and patches (Zostrix, Aspercreme Warming and others) are labeled for minor muscle and joint pain from arthritis, backache, strains and sprains. Qutenza, a prescription high-concentration skin system applied only by a healthcare professional, is FDA-approved for neuropathic pain of postherpetic neuralgia and of diabetic peripheral neuropathy of the feet. A prescriber might order compounded capsaicin for a strength or vehicle not manufactured or a combination with other topical pain ingredients. Compounded preparations are not FDA-approved and require a prescription.
Capsaicin has no boxed warning. Expect burning, stinging, redness or itching where it is applied, especially at first; stop and call your prescriber for severe burning, blistering or swelling. Never put it on broken or infected skin or near the eyes, nose or mouth, and wash your hands after applying. Do not bandage the area, add heat from a heating pad or hot shower, or apply right before exercise; heat sharply increases the burn. Dried residue can irritate the airway, and treated skin may become more sun sensitive. Capsaicin barely enters the bloodstream and is not expected to interact with oral medicines, though it can briefly raise blood pressure. Tell your prescriber if you are allergic to chili peppers. LactMed considers infant exposure unlikely but says to keep it off the nipple area and away from the infant's skin. If side effects bother you, talk to your prescriber or pharmacist.
Capsaicin is a selective TRPV1 agonist. Initial activation produces calcium influx, depolarization and burning; sustained or high-concentration exposure defunctionalizes TRPV1-expressing nociceptors through mitochondrial inhibition, cytoskeletal breakdown and terminal retraction, with substance P depletion now regarded as a correlate rather than the mechanism. Analgesia persists until reinnervation, typically a few months. Systemic absorption is minimal; after the 8% system, plasma levels were low and transient with an elimination half-life around 1.6 hours, and in vitro data show no meaningful CYP interaction. Labeled indications: Qutenza (capsaicin 8% topical system) for neuropathic pain of postherpetic neuralgia and diabetic peripheral neuropathy of the feet in adults, applied by a healthcare professional; OTC low-concentration products for minor musculoskeletal pain. Prescribers have ordered compounded capsaicin for osteoarthritis, chronic low back pain, localized pruritus and neuropathic pain, uses reviewed by Anand and Bley (Br J Anaesth 2011), who describe modest benefit from low-concentration products limited by burning and adherence. Strength, vehicle and application schedule are per prescriber. Monitoring: application-site reactions, transient blood pressure rise during high-concentration exposure, and sensory function with repeated high-strength use; the Qutenza label reports severe burns with unapproved use or application over damaged skin. Not a controlled substance.
Wash your hands and blow your nose gently. Prime the pump if your label says to. Keep your head upright, close one nostril with a finger, insert the tip into the other nostril and breathe in slowly while pressing the pump the number of times on your label. Repeat in the other nostril if directed. Wipe the nozzle, recap, and wash your hands. Do not share the bottle.
Nasal sprays are aqueous. Under USP <795>, a preserved spray usually carries a beyond-use date of up to 35 days at room temperature or refrigerated, and an unpreserved one 14 days refrigerated. Follow the storage line on your label, keep out of reach of children, and discard after the beyond-use date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Inhale intranasally
